Baxter International Inc. Analysis – September 2015 Update $BAX

Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Most Undervalued Companies for the Defensive Investor – August 2015.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how Baxter International Inc. (BAX) fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.


To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Here is a free sample valuation pdf, and here is a post detailing what can be found within each individual company’s valuation.


Downloadable PDF version of this valuation:

ModernGraham Valuation of BAX – September 2015

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $19,658,480,312 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 2.30 Pass
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 28.73% Fail
6. Moderate PEmg Ratio PEmg < 20 10.55 Pass
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 2.47 Pass
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 2.30 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 1.47 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

Stage 2: Determination of Intrinsic Value

BAX value Chart September 2015

EPSmg $3.41
MG Growth Estimate 0.79%
MG Value $34.39
Opinion Fairly Valued
MG Value based on 3% Growth $49.50
MG Value based on 0% Growth $29.02
Market Implied Growth Rate 1.02%
Current Price $36.01
% of Intrinsic Value 104.72%

Baxter International qualifies for both the Defensive Investor and the Enterprising Investor.  The Defensive Investor’s only initial concern is the insufficient earnings growth over the last ten years, while the Enterprising Investor is only concerned with the level of debt relative to the net current assets.  As a result, all value investors following the ModernGraham approach based on Benjamin Graham’s methods should feel comfortable proceeding with further research into the company.

As for a valuation, the company appears to be fairly valued after growing its EPSmg (normalized earnings) from $3.24 in 2011 to an estimated $3.41 for 2015.  This level of demonstrated earnings growth supports the market’s implied estimate of 1.02% annual earnings growth over the next 7-10 years.  As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value within a margin of safety relative to the price.

The next part of the analysis is up to individual investors, and requires discussion of the company’s prospects.  What do you think?  What value would you put on Baxter International (BAX)?  Where do you see the company going in the future?  Is there a company you like better?  Leave a comment on our Facebook page or mention @ModernGraham on Twitter to discuss.

Stage 3: Information for Further Research

BAX Charts September 2015

Net Current Asset Value (NCAV) -$13.72
Graham Number $25.38
PEmg 10.55
Current Ratio 2.30
PB Ratio 2.47
Dividend Yield 5.78%
Number of Consecutive Years of Dividend Growth 9



Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Total Current Assets $14,497,000,000
Total Current Liabilities $6,312,000,000
Long-Term Debt $12,054,000,000
Total Assets $30,015,000,000
Intangible Assets $5,876,000,000
Total Liabilities $22,027,000,000
Shares Outstanding (Diluted Average) 549,000,000

Earnings Per Share History

Next Fiscal Year Estimate $1.95
Dec14 $4.56
Dec13 $3.66
Dec12 $4.18
Dec11 $3.88
Dec10 $2.39
Dec09 $3.59
Dec08 $3.16
Dec07 $2.61
Dec06 $2.13
Dec05 $1.52
Dec04 $0.63
Dec03 $1.45
Dec02 $1.26
Dec01 $1.00
Dec00 $1.24
Dec99 $1.35
Dec98 $0.55
Dec97 $0.53
Dec96 $1.23
Dec95 $1.18

Earnings Per Share – ModernGraham History

Next Fiscal Year Estimate $3.41
Dec14 $4.01
Dec13 $3.67
Dec12 $3.60
Dec11 $3.24
Dec10 $2.88
Dec09 $2.95
Dec08 $2.42
Dec07 $1.92
Dec06 $1.52
Dec05 $1.20
Dec04 $1.06
Dec03 $1.27
Dec02 $1.15
Dec01 $1.04
Dec00 $1.04
Dec99 $0.94

Recommended Reading:

Other ModernGraham posts about the company

Baxter International Analysis – June 2015 Update $BAX
18 Companies in the Spotlight This Week – 3/15/15
Baxter International Inc. Quarterly Valuation – March 2015 $BAX
22 Companies in the Spotlight This Week – 11/29/14
Baxter Corporation Quarterly Valuation – November 2014 $BAX

Other ModernGraham posts about related companies

Cerner Corporation Analysis – September 2015 Update $CERN
Boston Scientific Inc. Analysis – September 2015 Update $BSX
Intuitive Surgical Inc. Analysis – September 2015 Update $ISRG
Dentsply International Inc. Analysis – August 2015 Update $XRAY
Becton Dickinson & Company Analysis – August 2015 Update $BDX
Align Technology Analysis – Initial Coverage $ALGN
Varian Medical Systems Inc Analysis – August 2015 Update $VAR
Psychemedics Corporation Analysis – August 2015 Update $PMD
C.R. Bard Inc. Analysis – August 2015 Update $BCR
Thermo Fisher Scientific Inc. Analysis – 2015 Update $TMO


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

One thought on “Baxter International Inc. Analysis – September 2015 Update $BAX

  1. antonio ramos says:

    I want to now the MG value can you tell me?

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.